Maze Therapeutics (MAZE) Shares Outstanding (Diluted Average) (2024 - 2026)
Maze Therapeutics recorded quarterly Shares Outstanding (Diluted Average) of $53.9 million in Q1 2026, up 25.41% quarter-over-quarter from $43.0 million in Q4 2025, and up 88.26% year-over-year from $28.6 million in Q1 2025.
Maze Therapeutics' Shares Outstanding (Diluted Average) history runs 3 years deep, the most recent figure standing at $53.9 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 88.26% year-over-year to $53.9 million; the TTM figure through Mar 2026 stood at $53.9 million (up 88.26% YoY), while the FY2025 annual figure was $43.0 million, up 1474.04% from the prior year.
- Shares Outstanding (Diluted Average) came in at $53.9 million for Q1 2026 at Maze Therapeutics, up from $43.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $53.9 million in Q1 2026 to a low of $2.3 million in Q1 2024.
- A 3-year average of $24.5 million and a median of $28.6 million in 2025 frame the typical range for Shares Outstanding (Diluted Average).
- Across the five-year window, Shares Outstanding (Diluted Average) jumped 1474.04% in 2025 and jumped 88.26% in 2026, its largest moves.
- Maze Therapeutics' Shares Outstanding (Diluted Average) stood at $2.7 million in 2024, then surged by 1474.04% to $43.0 million in 2025, then grew by 25.41% to $53.9 million in 2026.
- According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $53.9 million, $43.0 million, and $39.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | 53.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.90 Mn |
| Dec 31, 2025 | 42.98 Mn |
| Sep 30, 2025 | 39.46 Mn |
| Jun 30, 2025 | 43.80 Mn |
| Mar 31, 2025 | 28.63 Mn |
| Dec 31, 2024 | 2.73 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 3.27 Mn |
| Mar 31, 2024 | 2.34 Mn |